Compare FET & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | ALT |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.7M | 415.3M |
| IPO Year | 2007 | 2005 |
| Metric | FET | ALT |
|---|---|---|
| Price | $54.88 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 257.7K | ★ 2.9M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $791,474,000.00 | $41,000.00 |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $9.75 | $756,308.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $12.78 | $2.91 |
| 52 Week High | $63.58 | $7.73 |
| Indicator | FET | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 35.87 |
| Support Level | $25.54 | $3.40 |
| Resistance Level | $63.58 | $4.25 |
| Average True Range (ATR) | 2.89 | 0.23 |
| MACD | -0.90 | -0.05 |
| Stochastic Oscillator | 13.77 | 16.38 |
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.